Neuroscience
Available on Demand
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
| 6 min read
QurAlis researchers have developed QRL-101, a new drug candidate that targets overactive neurons to prevent cell death in ALS.
| 4 min read
Biotech and pharma leaders reveal the neurological therapies in development that they’re most excited about.
| 3 min read
A statistical model using two measures of brain activity could anticipate if people given an injection would be in severe pain for the next month.
| 4 min read
In a Phase 2b trial, Khondrion’s sonlicromanol led to significant health benefits for patients with mitochondrial disease linked to a common mutation.
| 3 min read
A gene therapy targeting organs beyond the brain could improve quality of life and possibly extend survival in children with the neurodegenerative disease.
| 3 min read
Unlike in other brain regions, levels of the neurotransmitter decrease in the cerebellum when anxiety is high, suggesting a potential new drug target.
| 3 min read
Vertex Pharmaceuticals’ drug, Journavx, blocks a sodium channel outside of the brain. Experts hope that this non-addictive pain drug may be the first of many.
| 4 min read
People and mice with ALS-linked mutations show altered sleep patterns early in life. Modifying sleep hormone levels normalized sleep cycles in mice.
| 3 min read
Levels of neuroactive steroids during the third trimester of pregnancy may indicate postpartum depression risk.
| 4 min read
Targeting a gut bacterial species or its metabolites could potentially improve diabetes management by reducing sugar preferences.
| 8 min read
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
